Verrica downgraded to sector perform by RBC Capital

VRCA Stock  USD 1.00  0.01  1.01%   
About 63% of all Verrica Pharmaceuticals' investors are looking to take a long position. The analysis of overall sentiment of trading Verrica Pharmaceuticals stock suggests that some investors are interested at this time. The current market sentiment, together with Verrica Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Verrica Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
RBC Capital Markets has downgraded Verrica Pharmaceuticals to sector perform from outperform, citing problems with the launch of its product YCANTH. Read more here.

Read at seekingalpha.com
seekingalpha News
  

Verrica Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Verrica Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Verrica Pharmaceuticals Fundamental Analysis

We analyze Verrica Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verrica Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verrica Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash And Equivalents

Cash And Equivalents Comparative Analysis

Verrica Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers. Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Verrica Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Verrica Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Verrica Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Verrica Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Verrica Pharmaceuticals Related Equities

FENCFennec Pharmaceuticals   12.71   
0%
100.0%
VIGLVigil Neuroscience   6.33   
0%
49.0%
ASNDAscendis Pharma   5.85   
0%
46.0%
ETONEton Pharmaceuticals   4.47   
0%
35.0%
NUVBNuvation Bio   3.70   
0%
29.0%
ABOSAcumen Pharmaceuticals   2.60   
0%
20.0%
VRNAVerona Pharma   2.51   
0%
19.0%
PLXProtalix Biotherapeutics   1.81   
0%
14.0%
PLRXPliant Therapeutics   1.01   
0%
7.0%
CNTBConnect Biopharma   1.01   
0%
7.0%
EWTXEdgewise Therapeutics   0.69   
0%
5.0%
LRMRLarimar Therapeutics   0.49   
0%
3.0%
ARQTArcutis Biotherapeutics   0.98   
7.0%
0%
ELDNEledon Pharmaceuticals   1.47   
11.0%
0%
IVAInventiva   1.50   
11.0%
0%
CRNXCrinetics Pharmaceuticals   1.70   
13.0%
0%

Complementary Tools for Verrica Stock analysis

When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Volatility Analysis
Get historical volatility and risk analysis based on latest market data